{{medical}}
{{多個問題|
{{expand|time=2012-04-25T04:09:56+00:00}}
{{expert-subject|time=2012-04-25T04:09:56+00:00}}
{{refimprove|time=2012-04-25T04:09:56+00:00}}
}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 437165565
| IUPAC_name = (''RS'')-5-[1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl]-2-
| image = Amosulalol.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|amosulalol}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 85320-68-9
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 2169
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2084
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = C69JI1BAU8
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07451
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 152231

<!--Chemical data-->
| chemical_formula =  
| C=18 | H=24 | N=2 | O=5 | S=1 
| molecular_weight = 380.45 g/mol
| smiles = CC1=C(C=C(C=C1)C(CNCCOC2=CC=CC=C2OC)O)S(=O)(=O)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LVEXHFZHOIWIIP-UHFFFAOYSA-N
}}

'''氨磺洛尔'''（Amosulalol）又称阿膜索罗，神经系统抗肾上腺素药。药理作用阻断α及β受体，可降低血压，其降压效价强度为[[普萘洛尔|普萘洛尔]]的1/16— 1/12。可用于原发性高血压及嗜铬细胞瘤性高血压，用药后血压下降迅速、持久。由日本山之内制药公司研制与开发,于1988年首次上市。<ref>{{cite journal|author=郑雪珠|title=氨磺洛尔Amosulalol|journal=药学进展|issue=04|date=1991年4月}}</ref>

==参考资料==
<references/>

{{Beta blockers}}

[[Category:药物|Category:药物]]